Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal

Year.

On December 15, 2022, the Board of Directors (the "Board") of BioMarin Pharmaceutical Inc. (the "Company") approved and adopted the Company's Amended and Restated Bylaws (as so amended, the "Amended Bylaws"), effective as of December 15, 2022.

The amendments effected by the Amended Bylaws:



    •     Update provisions regarding the manner of giving notice of a meeting of
          stockholders and the manner of waiving notice of a meeting of
          stockholders to align with Delaware General Corporation Law (the "DGCL");



    •     Update provisions regarding the manner in which a meeting of stockholders
          may be adjourned without having to provide additional notice and the
          availability of the list of stockholders entitled to vote at a meeting of
          stockholders, in each case to reflect recent amendments to the DGCL;



    •     Require that a stockholder directly or indirectly soliciting proxies from
          other stockholders must use a proxy card color other than white;



    •     Update procedural mechanics and disclosure requirements in connection
          with stockholder nominations of directors and submission of certain
          stockholder proposals made in connection with annual and special meetings
          of stockholders, including addressing matters relating to Rule 14a-19
          under the Securities Exchange Act of 1934, as amended (the "Universal
          Proxy Rules"), such as providing the Company a remedy if a stockholder
          fails to satisfy certain requirements under the Universal Proxy Rules and
          requiring stockholders who intend to use the Universal Proxy Rules to
          provide reasonable evidence of the satisfaction of certain requirements
          under the Universal Proxy Rules at least five business days before the
          applicable meeting; and



    •     Make certain other administrative, modernizing, clarifying, and
          conforming changes.

The preceding description of the changes contained in the Amended Bylaws does not purport to be complete and is qualified in its entirety by reference to the Amended Bylaws, a copy of which is attached hereto as Exhibit 3.1 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.

Exhibit
  No.        Description

3.1            Amended and Restated Bylaws of BioMarin Pharmaceutical Inc.

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document).



--------------------------------------------------------------------------------

© Edgar Online, source Glimpses